Cite
APA Citation
Varghese, A. M., Howard, D. R., Pocock, C., Rawstron, A. C., Follows, G., McCarthy, H., Dearden, C., Fegan, C., Milligan, D., Smith, A. F., Gregory, W., Hillmen, P., & , (2017). eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. British journal of haematology, 176, 573–582. http://access.bl.uk/ark:/81055/vdc_100041767516.0x000035